MAT-LINK has been awarded additional funding to expand the project that monitors maternal, infant and child health outcomes associated with medication for opioid usedisorder (OUD) during pregnancy. This expansion will add geographically diverse clinical sites with varied racial, ethnic and socioeconomic characteristics, and extend child follow-up data collection from 2 years through 6 years of age for all sites. The Centers for Disease Control and Prevention (CDC) funded PHII to develop MAT-LINK.
Three new outstanding institutions will join MAT-LINK as Phase II clinical sites:
- University of New Mexico
- University of Rochester
- University of South Florida
The Phase II clinical sites will join the established project team with PHII, CDC, Phase I clinical sites, federal agency representatives, and clinical and public health partners to collaborate on improving knowledge about maternal, infant and child health outcomes associated with medication for opioid use disorder during pregnancy.
Read more about how the MAT-LINK project is shedding light on the opioid epidemic.